Neuronetics Stock Price, News & Analysis

Neuronetics, Inc. (NASDAQ: STIM) announced the grant of 32,258 Restricted Stock Units (RSUs) to Rusty Page, VP Operations, as an inducement for his new role. This award, valued based on the December 1, 2022, closing stock price, will vest over three years subject to continued service. Neuronetics focuses on improving mental health through its NeuroStar Advanced Therapy, which is FDA-cleared for major depressive disorder and other conditions. The company emphasizes its commitment to transforming lives through innovative treatments backed by extensive clinical data.

Neuronetics (NASDAQ: STIM) has been recognized as a 2022 bronze winner by the Merit Awards in the HealthTech Patient Care category for its NeuroStar Advanced Therapy. The award highlights the company's commitment to enhancing patient care for those suffering from neurohealth disorders. With over 5 million treatments delivered, NeuroStar stands out as a leader in transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) and other psychiatric conditions. This accolade underscores Neuronetics' ongoing collaboration with the FDA to expand treatment indications.

Neuronetics, a medical technology company listed on NASDAQ as STIM, announced the granting of 69,758 Restricted Stock Units (RSUs) to ten new non-executive employees as part of their inducement to join the company. The RSUs vest in three equal installments over three years, contingent on continued employment. This move follows NASDAQ Listing Rule 5635(c)(4) and aims to enhance talent retention and attract skilled professionals in their field. Neuronetics focuses on neurohealth technologies, notably the NeuroStar system for treating mental health disorders.

Neuronetics, Inc. (NASDAQ: STIM) reported a 20% increase in Q3 2022 revenue, totaling $16.5 million, compared to $13.8 million in Q3 2021. The U.S. treatment session revenue reached a record $11.9 million, with a 51% rise in NeuroStar System revenue. The company raised its full-year revenue guidance to $63-64 million. Positive regulatory updates include FDA clearance for the D-Tect™ MT Accessory, and multiple TMS coverage policies improving patient access. However, operating expenses increased by 14.6% to $20.4 million, with a net loss of $(7.6) million, slightly better than the previous year.

Neuronetics, Inc. (NASDAQ: STIM) has been awarded the 2022 bronze medal in the HealthTech category by the Merit Awards for its NeuroStar Advanced Therapy, a notable innovation in mental health treatment.

NeuroStar offers a non-drug solution for psychiatric disorders, particularly depression. Over 4.8 million treatments have been delivered, supported by extensive clinical data. CEO Keith J. Sullivan emphasized the company's commitment to improving patient lives and continuing innovation in neurohealth.

MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) plans to release its Q3 2022 financial results on November 8, 2022, prior to market open. A conference call will follow at 8:30 a.m. ET to discuss the results, with a live webcast available. Neuronetics focuses on improving mental health through its NeuroStar Advanced Therapy, a non-invasive treatment for mood disorders like major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). NeuroStar has delivered over 4.8 million treatments and is backed by extensive clinical data.

Neuronetics (NASDAQ: STIM) has announced updates to its TrakStar platform to improve the patient management experience for NeuroStar providers. These enhancements streamline patient identification and re-treatment processes, supporting clinicians in managing treatment for drug-resistant depression. The upgrades include a simplified interface, automated patient candidate generation through the PHQ-10 tool, and improved benefits investigation integration. This marks the third enhancement of the TrakStar platform in 2022, reflecting Neuronetics’ ongoing commitment to innovation and support for mental health treatment.

Neuronetics announced the grand opening of NeuroStar University in Charlotte, North Carolina, the first training center in the TMS industry aimed at enhancing best practices for mental health treatment.

This facility will provide comprehensive education to help practices deliver optimal outcomes with NeuroStar Advanced Therapy. The curriculum includes Learn, Connect, and Grow components to enhance treatment quality for patients with drug-resistant depression.

Currently, NeuroStar University offers free two-day classes for existing practices.

Neuronetics, Inc. (NASDAQ: STIM) has granted inducement awards to 12 new non-executive employees, complying with NASDAQ Listing Rule 5635(c)(4). A total of 55,680 Restricted Stock Units (RSUs) were awarded, with vesting occurring in three equal installments over three years, contingent on continued service. The RSUs are part of the Neuronetics 2020 Inducement Plan. As a leader in neuroscience and TMS treatment, Neuronetics aims to enhance life quality for those with neurohealth disorders, including major depressive disorder.